AKT1 and sarcoma: In studies including pediatric models, this inhibitor has shown promising results in vitro, reducing cell viability and colony formation and inducing apoptosis in sarcoma cells (EWS, OS and RMS) without affecting human osteoblast and osteocyte cells (normal bone cells); effects were improved by combination with MK2206, an AKT-specific inhibitor [795,796].